April 21, 2008 8:40 PM
- Text
Guerrilla Marketing, Pharma Style
(MoneyWatch) The pharma blogosphere is buzzing about what appears to be a new "guerilla marketing" campaign for the over-the-counter allergy drug Zyrtec.
According to one blogger in Boston and another in New York, many of these seemingly handwritten flyers have been seen taped to telephone poles, scaffolds and other post-like structures over the past week. (Click on the image at left for a larger version, courtesy of PharmaGossip.) Some anecdotal sightings have even reported a few of the tabs torn off. The phone number connects to a recorded message touting Zyrtec's advantages and eventually directs callers to a Zyrtec Web site.
In case it's not immediately clear, this college-town-style flyer is actually a negative ad attacking rival allergy drug Claritin, which is also sold over the counter. No word yet on whether Zyrtec's maker -- Johnson & Johnson subsidiary McNeil-PPC -- is taking responsibility for the campaign, although I'll let you know if I can find anything out.
Whatever your feelings about consumer-directed drug ads, it's hard not to admire the cleverness of this approach. Given the increasing pressure on drugmakers from generic competition, Congress and the FDA, it wouldn't surprise me at all to see other pharmas exploring similarly creative alternatives to traditional drug marketing. Whether it will turn out to be effective is an entirely different issue, and there I have my doubts -- although you have to admit that it certainly doesn't cost much, either.
There's one more catch: If this scheme is legal, it's probably only because Zyrtec doesn't require a prescription, which would necessitate a lengthy disclosure of side effects and other information in any ad. On the other hand, simply omitting the name of the advertised drug might get you around that requirement, too.
According to one blogger in Boston and another in New York, many of these seemingly handwritten flyers have been seen taped to telephone poles, scaffolds and other post-like structures over the past week. (Click on the image at left for a larger version, courtesy of PharmaGossip.) Some anecdotal sightings have even reported a few of the tabs torn off. The phone number connects to a recorded message touting Zyrtec's advantages and eventually directs callers to a Zyrtec Web site.In case it's not immediately clear, this college-town-style flyer is actually a negative ad attacking rival allergy drug Claritin, which is also sold over the counter. No word yet on whether Zyrtec's maker -- Johnson & Johnson subsidiary McNeil-PPC -- is taking responsibility for the campaign, although I'll let you know if I can find anything out.
Whatever your feelings about consumer-directed drug ads, it's hard not to admire the cleverness of this approach. Given the increasing pressure on drugmakers from generic competition, Congress and the FDA, it wouldn't surprise me at all to see other pharmas exploring similarly creative alternatives to traditional drug marketing. Whether it will turn out to be effective is an entirely different issue, and there I have my doubts -- although you have to admit that it certainly doesn't cost much, either.
There's one more catch: If this scheme is legal, it's probably only because Zyrtec doesn't require a prescription, which would necessitate a lengthy disclosure of side effects and other information in any ad. On the other hand, simply omitting the name of the advertised drug might get you around that requirement, too.
-
David Hamilton is the assistant managing editor of CNET News. He has been writing and editing business and tech coverage for about two decades -- the majority of that at the Wall Street Journal in both Tokyo and San Francisco.
Follow on Twitter »
Latest Now in MoneyWatch
- Insurers respond cautiously to contraceptive plan
- Judge: Legally, breastfeeding not related to pregnancy
- Budget deficit drops to $27 billion in January
- Why the Powerball Jackpot is part of my investment strategy
- Is the new VW Beetle diesel worth the money?
- Consumer sentiment highlights risks to recovery
- Valentine blues? 10 best cities to be single
- December trade deficit widens to $48.8 billion
- Alcatel-Lucent returns to profit in 2011
- 6 things never to say in a performance review
- $26B mortgage deal: Who gets the money?
- Friendly's CEO steps down
- Quarterly loss hits $3.3B at Postal Service
- Greeks rail against cuts as EU demands more
- 6 things you should never share on Facebook
- Make moves now to increase financial aid
- Valentine's Day: 9 places to save
Latest CBS News Headlines
on Facebook
on CBS News
- US Embassy to improve processing visas to Chinese
- Officials: 2 held in death of Afghan peace broker
- Turkmens to vote in one-horse race
- China: Syria veto won't hurt cooperation with US
on Facebook
- Adele sings a cappella for Anderson Cooper
- Josh Powell had "incestuous" images on his home computer, authorities say
on CBS News






